Fosun Hanlin (02696): The first patient in Japan completed the dosing of Hanshi (sulreotide monoclonal antibody injection) combined with chemotherapy as first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC).

Wisdom Financial APP News, Fuhong Hanlin (02696) announced recently that a bridging trial of Hanuchu (Sulirumab Injection) in combination with chemotherapy (carboplatin-etoposide) for extensive-stage small cell lung cancer (ES-SCLC) has completed the first patient dosing in Japan. This trial was conducted based on an implied permit from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for a Phase 2 clinical trial, to support future market application of Hanuchu in Japan. Previously, an international multicenter Phase 3 clinical trial comparing Hanuchu or placebo in combination with chemotherapy (carboplatin-etoposide) for first-line treatment of ES-SCLC patients reached the primary endpoint of overall survival (OS) in December 2021.